FutureLife expands its footprint in the UK
August 2, 2022
FutureLife expands its footprint in the UK through a strategic partnership transaction with The Centre for Reproductive and Genetic Health (‘CRGH’), a leading privately focused IVF clinic located in Central London.
FutureLife, a leading Pan-European provider of IVF and related genetics services performing in excess of 40,000 IVF cycles annually, backed by CVC Capital Partners (‘CVC’) and Hartenberg Holding (‘Hartenberg’), has announced the acquisition of CRGH, a leading privately focused IVF clinic located in Central London.
CRGH is the largest private fertility clinic in the attractive London private IVF market, performing more than 3,200 egg collections per year. The company, located near Harley Street, is well-established in providing best-in-class treatment and care to patients, with over 30+ years of experience, having been set up by founder and current Medical Director, Paul Serhal, a world-renowned pioneer of IVF services who will continue to play a key role in the company. CRGH delivers clinical excellence through its leading clinical and embryology teams, resulting in the clinic achieving one of the highest success rates in the UK.
FutureLife is a leading European provider of IVF and related genetics services, with 40+ well-invested clinics that perform in excess of 40,000 IVF cycles annually, IVF add-on and laboratory services, as well as a series of biological and surgical treatments. FutureLife was joined earlier this year by a new investor, CVC, a leading global private equity firm and, as such, the group has been focused on expanding its footprint in a number of key European geographies, including the UK where FutureLife currently has a footprint through London-based City Fertility. Following the acquisition of CRGH, FutureLife has strengthened its London footprint and will operationally align City Fertility and CRGH to enable knowledge sharing and implementation of best practices across both clinics.
Matěj Stejskal, CEO and shareholder of FutureLife: “CRGH and the FutureLife group share the same culture, vision and principles in providing best-in-class care for our patients. The UK is an important strategic market for us and we look forward to growing our leading presence in this market through our partnership with CRGH. Our approach is based on harmonization as we identify and share the best knowledge and medical practices across our platform, whilst ensuring that clinics maintain their strong clinical autonomy and brand. We look for partners that are able to help us grow our business further and bring excellence to our operations. CRGH had these parameters alongside and through exceptional people and we look forward to their joining the FutureLife group.”
Jozef Janov, Managing Partner at Hartenberg added: “The partnership with CRGH is another important milestone in FutureLife’s growth story in becoming a European leader in IVF. It will bring us additional know-how, clinical experience and excellence in the care provided to patients throughout our clinics. It is also the first acquisition that we are completing with our new partners from CVC. Together with management, we remain focused on further acquisitions in the fragmented UK market.”
Cathrin Petty, Managing Partner at CVC: “We are delighted that CRGH has chosen to partner with FutureLife. This continues to deliver our strategy to build out the first-class Future life platform into new markets. Dr. Serhal and his team are world-renowned for their clinical and scientific excellence and we will continue to invest behind them.”
Paul Serhal, founder and Medical Director of CRGH: “Partnering with FutureLife will support the strategic development of CRGH and build on our core values of clinical excellence, success through continual innovation, and bespoke patient care. The growing FutureLife community provides breadth and depth of leadership in IVF and I look forward to the next chapter of this exciting journey.”
Jonathon Lawrence, who will lead the combined operations of CRGH and City Fertility as FutureLife’s CEO of UK: “This partnership gives us the foundation to build on the success of CRGH in the UK as part of the FutureLife family. I look forward to leading this new joint venture through a period of strong, sustained growth.”
FutureLife is one of Europe’s largest and fastest growing providers of IVF services with a leading presence across each of the markets in which it operates. The Group is also one of the largest fertility service providers worldwide with over 40,000 IVF cycles performed annually. FutureLife is co-owned by Hartenberg and CVC. www.futurelife.eu/en/home/
Hartenberg is an investment company focused on assets in the Central European Region, primarily Czech Republic, Slovakia and Poland and is able to be a long-term investor in companies it acquires. Hartenberg invests in healthcare, e-commerce, FMCG, and real estate companies with the current value of its portfolio exceeding €600 million. The group employs more than 4,500 people. For further information about Hartenberg please visit: www.hartenbergcapital.com.
CVC is a leading private equity and investment advisory firm with a network of 25 offices throughout Europe, Asia and the US, with approximately €125 billion of assets under management. Since its founding in 1981, CVC has secured commitments in excess of €163 billion from some of the world’s leading institutional investors across its private equity and credit strategies. Funds managed or advised by CVC are invested in more than 110 companies worldwide, which have combined annual sales of over €100 billion and employ more than 550,000 people. For further information about CVC please visit: www.cvc.com.